Company intelligence / Profile preview

Syntrix Pharmaceuticals

Auburn, Washington, United Statessyntrixbio.com ↗
Ownership
Private
Development stage
Phase 2
01

Overview

Syntrix Pharmaceuticals has demonstrated clinical activity with its lead candidate SX‑682—a dual CXCR1/2 inhibitor—in patients with myelodysplastic syndromes who failed front-line hypomethylating agents. The company also has additional assets in pain management and autoimmunity at various stages of development. Its pipeline includes both internally discovered small molecules and externally sourced innovations.

Therapeutic areas
OncologyImmunologyNeurology
Modalities
Small moleculesBiologics (proteins or antibodies)
Industry
Biotech
02

Drug pipeline

2 assets

SX-682

2

1 more asset in the full pipeline.

Request access →
03

Partnerships

Collaborations with academic researchers such as Dr. Keith Flaherty at Massachusetts General Hospital Cancer Center for clinical trialsgeneral partnerships with research organizations and manufacturers to support R&D and clinical supply chain needs.[5][8]

Beyond the preview

Go deeper on Syntrix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntrix Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call